Clinical Trial Results:
            A Phase 2B, Multi-center, Randomized, Double- blind, Parallel Group, Placebo-controlled, Dose Ranging Study Comparing the Efficacy, Safety, and Pharmacokinetics of Intravenous Infusions of ABT − 874 vs. Placebo in Subjects with Moderately to Severely Active Crohn's Disease
    
    Due to the EudraCT – Results system being out of service between 31 July 2015 and 12 January 2016, these results have been published in compliance with revised timelines
| 
                 Summary 
         | 
        |
    EudraCT number  | 
        2008-004919-36 | 
    Trial protocol  | 
        AT BE SE DK | 
    Global completion date  | 
        
                                    30 Mar 2010
                             
         | 
    
| 
                 Paediatric regulatory details 
         | 
        |
    Is the trial part of an agreed EMA paediatric investigation plan?  | 
        
                                        No
                                 
         | 
    
    Is the trial in scope of article 45 of Regulation (EC) No 1901/2006?  | 
        
                                        No
                                 
         | 
    
    Is the trial in scope of article 46 of Regulation (EC) No 1901/2006?  | 
        
                                        No
                                 
         | 
    
| 
                 Results information 
         | 
        |
    Results version number  | 
        v1(current) | 
    This version publication date  | 
        
                                    08 Dec 2016
                             
         | 
    
    First version publication date  | 
        
                                    08 Dec 2016
                             
         | 
    
    Other versions  | 
        |
    Summary report(s)  | 
                                M10-222 Study | 
    
            Note: The legislation allows summary attachments to be posted instead of the full dataset for this trial. Refer to            Commission Guideline 2012/C 302/03
            for further information.